TY  - JOUR
AU  - Micić, Sava
AU  - Lalić, Nataša
AU  - Đorđević, Dejan
AU  - Bojanić, Nebojša
AU  - Bogavac-Stanojević, Nataša
AU  - Busetto, Gian Maria
AU  - Virmani, Ashraf
AU  - Agarwal, Ashok
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3347
AB  - Carnitine is essential for energy metabolism and spermatozoa maturation. Combining L-carnitine and L-acetylcarnitine with micronutrients has been investigated as a treatment for infertility in men. We evaluated the effects of a therapeutic formulation, Proxeed Plus, on sperm parameters in oligoasthenozoospermic men. This prospective, randomised, double-blind, placebo-controlled clinical trial involved 175 males (19-44 years) with idiopathic oligoasthenozoospermia who failed to impregnate their partners (12 months). Males received Proxeed Plus or placebo for 3 and 6 months. Sperm volume, progressive motility and vitality significantly (p  lt  0.001) improved after 6 months compared to baseline. Sperm DNA fragmentation index significantly decreased compared to baseline (p  lt  0.001) and the 3-month therapy (p = 0.014) in treated men. Increased seminal carnitine and alpha-glucosidase concentration also positively correlated with improved progressive motility. Decreased DNA fragmentation index was the good predictor of progressive sperm motility >10%, and simultaneous measurement of changes in sperm vitality and DNA fragmentation index gave the highest probability of sperm motility 10% (AUC = 0.924; 95% CI = 0.852-0.996; p  lt  0.001). Logistic regression analyses revealed DNA fragmentation index decrease as the only independent predictor of sperm motility 10% (OR = 1.106; p = 0.034). We have demonstrated the beneficial effects of carnitine derivatives on progressive motility, vitality and sperm DNA fragmentation. Combining metabolic and micronutritive factors is beneficial for male infertility.
PB  - Wiley, Hoboken
T2  - Andrologia
T1  - Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia
VL  - 51
IS  - 6
DO  - 10.1111/and.13267
ER  - 

@article{
author = "Micić, Sava and Lalić, Nataša and Đorđević, Dejan and Bojanić, Nebojša and Bogavac-Stanojević, Nataša and Busetto, Gian Maria and Virmani, Ashraf and Agarwal, Ashok",
year = "2019",
abstract = "Carnitine is essential for energy metabolism and spermatozoa maturation. Combining L-carnitine and L-acetylcarnitine with micronutrients has been investigated as a treatment for infertility in men. We evaluated the effects of a therapeutic formulation, Proxeed Plus, on sperm parameters in oligoasthenozoospermic men. This prospective, randomised, double-blind, placebo-controlled clinical trial involved 175 males (19-44 years) with idiopathic oligoasthenozoospermia who failed to impregnate their partners (12 months). Males received Proxeed Plus or placebo for 3 and 6 months. Sperm volume, progressive motility and vitality significantly (p  lt  0.001) improved after 6 months compared to baseline. Sperm DNA fragmentation index significantly decreased compared to baseline (p  lt  0.001) and the 3-month therapy (p = 0.014) in treated men. Increased seminal carnitine and alpha-glucosidase concentration also positively correlated with improved progressive motility. Decreased DNA fragmentation index was the good predictor of progressive sperm motility >10%, and simultaneous measurement of changes in sperm vitality and DNA fragmentation index gave the highest probability of sperm motility 10% (AUC = 0.924; 95% CI = 0.852-0.996; p  lt  0.001). Logistic regression analyses revealed DNA fragmentation index decrease as the only independent predictor of sperm motility 10% (OR = 1.106; p = 0.034). We have demonstrated the beneficial effects of carnitine derivatives on progressive motility, vitality and sperm DNA fragmentation. Combining metabolic and micronutritive factors is beneficial for male infertility.",
publisher = "Wiley, Hoboken",
journal = "Andrologia",
title = "Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia",
volume = "51",
number = "6",
doi = "10.1111/and.13267"
}

Micić, S., Lalić, N., Đorđević, D., Bojanić, N., Bogavac-Stanojević, N., Busetto, G. M., Virmani, A.,& Agarwal, A.. (2019). Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. in Andrologia
Wiley, Hoboken., 51(6).
https://doi.org/10.1111/and.13267

Micić S, Lalić N, Đorđević D, Bojanić N, Bogavac-Stanojević N, Busetto GM, Virmani A, Agarwal A. Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. in Andrologia. 2019;51(6).
doi:10.1111/and.13267 .

Micić, Sava, Lalić, Nataša, Đorđević, Dejan, Bojanić, Nebojša, Bogavac-Stanojević, Nataša, Busetto, Gian Maria, Virmani, Ashraf, Agarwal, Ashok, "Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia" in Andrologia, 51, no. 6 (2019),
https://doi.org/10.1111/and.13267 . .

TY  - JOUR
AU  - Pejcić, Tomislav P.
AU  - Tulić, Cane
AU  - Lalić, Nataša V.
AU  - Glisić, Biljana D.
AU  - Ignjatović, Svetlana
AU  - Marković, Biljana
AU  - Hadzi-Đokić, Jovan B.
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1978
AB  - PEJCIC TP, TULIC CD, LALIC NV, GLISIC BD, IGNJATOVIC SD, MARKOVIC BB, HADZI-DJOKK JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression? Can J Urol 2013;20(2):6707-6713. Introduction: Urinary prostate-specific antigen (uPSA) can be used as additional parameter of benign prostatic hyperplasia (BPH) progression. Materials and methods: From January 2001 to December 2011, uPSA was determined in 265 patients with benign prostate. Based on total prostate volume (TPV), the patients with benign prostate were divided in two groups: TPV  lt 31 mL and TPV >= 31 mL. Additional three groups were formed upon MTOPS study criteria: non-progressive BPH group (TPV  lt  31 mL, PSA  lt  1.6 ng/mL, age  lt  62 yrs), intermediate group (one, or two parameters {TPV, PSA, age} increased) and progressive BPH group (TPV >= 31 ml, PSA >= 1.6 ng/mL, age >= 62 yrs). Results: Average uPSA values in the groups TPV  lt 31 mL and TPV 31 mL were 119.3 +/- 124.5 and 255.5 +/- 204.9 ng/mL, respectively and they were significantly different (p  lt  0.0001). Average uPSA values in the non-progressive BPH group, intermediate group and progressive BPH group were 86.8 +/- 82.4 ng/mL, 166.6 +/- 164.9 ng/mL and 274.9 +/- 208.3 ng/mL, respectively and they were significantly different (p  lt  0.0001). The level of uPSA correlated significantly with TPV (r = 0.32, p  lt  0.0001). The cut off uPSA level of 150 ng/mL discriminates the patients with non-progressive BPH and progressive BPH with specificity of 0.83 and sensitivity of 0.67. Conclusion: The level of uPSA reflects prostatic hormonal activity and correlates with TPV, PSA and age. UPSA level >= 150 ng/mL can be used as additional predictive parameter of BPH progression.
PB  - Canadian J Urology, St Laurent
T2  - Canadian Journal of Urology
T1  - Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
VL  - 20
IS  - 2
SP  - 6707
EP  - 6713
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1978
ER  - 

@article{
author = "Pejcić, Tomislav P. and Tulić, Cane and Lalić, Nataša V. and Glisić, Biljana D. and Ignjatović, Svetlana and Marković, Biljana and Hadzi-Đokić, Jovan B.",
year = "2013",
abstract = "PEJCIC TP, TULIC CD, LALIC NV, GLISIC BD, IGNJATOVIC SD, MARKOVIC BB, HADZI-DJOKK JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression? Can J Urol 2013;20(2):6707-6713. Introduction: Urinary prostate-specific antigen (uPSA) can be used as additional parameter of benign prostatic hyperplasia (BPH) progression. Materials and methods: From January 2001 to December 2011, uPSA was determined in 265 patients with benign prostate. Based on total prostate volume (TPV), the patients with benign prostate were divided in two groups: TPV  lt 31 mL and TPV >= 31 mL. Additional three groups were formed upon MTOPS study criteria: non-progressive BPH group (TPV  lt  31 mL, PSA  lt  1.6 ng/mL, age  lt  62 yrs), intermediate group (one, or two parameters {TPV, PSA, age} increased) and progressive BPH group (TPV >= 31 ml, PSA >= 1.6 ng/mL, age >= 62 yrs). Results: Average uPSA values in the groups TPV  lt 31 mL and TPV 31 mL were 119.3 +/- 124.5 and 255.5 +/- 204.9 ng/mL, respectively and they were significantly different (p  lt  0.0001). Average uPSA values in the non-progressive BPH group, intermediate group and progressive BPH group were 86.8 +/- 82.4 ng/mL, 166.6 +/- 164.9 ng/mL and 274.9 +/- 208.3 ng/mL, respectively and they were significantly different (p  lt  0.0001). The level of uPSA correlated significantly with TPV (r = 0.32, p  lt  0.0001). The cut off uPSA level of 150 ng/mL discriminates the patients with non-progressive BPH and progressive BPH with specificity of 0.83 and sensitivity of 0.67. Conclusion: The level of uPSA reflects prostatic hormonal activity and correlates with TPV, PSA and age. UPSA level >= 150 ng/mL can be used as additional predictive parameter of BPH progression.",
publisher = "Canadian J Urology, St Laurent",
journal = "Canadian Journal of Urology",
title = "Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?",
volume = "20",
number = "2",
pages = "6707-6713",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1978"
}

Pejcić, T. P., Tulić, C., Lalić, N. V., Glisić, B. D., Ignjatović, S., Marković, B.,& Hadzi-Đokić, J. B.. (2013). Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?. in Canadian Journal of Urology
Canadian J Urology, St Laurent., 20(2), 6707-6713.
https://hdl.handle.net/21.15107/rcub_farfar_1978

Pejcić TP, Tulić C, Lalić NV, Glisić BD, Ignjatović S, Marković B, Hadzi-Đokić JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?. in Canadian Journal of Urology. 2013;20(2):6707-6713.
https://hdl.handle.net/21.15107/rcub_farfar_1978 .

Pejcić, Tomislav P., Tulić, Cane, Lalić, Nataša V., Glisić, Biljana D., Ignjatović, Svetlana, Marković, Biljana, Hadzi-Đokić, Jovan B., "Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?" in Canadian Journal of Urology, 20, no. 2 (2013):6707-6713,
https://hdl.handle.net/21.15107/rcub_farfar_1978 .